Want to see GB:APTA full AI Analyst Report?
APTA Stock Chart & Stats
0.80 p
-0.01 p(-2.86%)
At close: 4:00 PM EST
0.80 p
-0.01 p(-2.86%)
Day’s Range― - ―
52-Week Range0.32 p - 1.57 p
Previous CloseN/A
Volume3.91M
Average Volume (3M)15.29M
Market Cap
£16.41M
Enterprise Value13.44M
Total Cash (Recent Filing)£1.53M
Total Debt (Recent Filing)£333.00K
Price to Earnings (P/E)―
Beta0.23
Next Earnings
Oct 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,455,144,000
10 Day Avg. Volume14,821,052
30 Day Avg. Volume15,285,032
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)5.32
Price to Sales (P/S)6.11
P/FCF Ratio-3.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized Aptamer PlatformAptamer Group's core business is a specialized platform for aptamer discovery and development used in diagnostics, research and potential therapeutics. This niche technical capability supports durable service revenues, partner integration and IP-driven differentiation over medium term horizons.
Improved Leverage ManagementAn improved debt-to-equity ratio reduces insolvency risk and increases financial flexibility. For a cash-burning biotech, better leverage creates more runway for R&D and partnerships and lowers refinancing pressure, sustaining operations while pursuing commercial milestones.
Free Cash Flow Trend ImprovingA modest improvement in free cash flow growth signals early progress toward cash discipline. If sustained, this can lengthen the funding runway, permit steady investment in platform advances, and reduce reliance on frequent external financing over the next several months.
Bears Say
Severe Revenue DeclineA near-total collapse in revenue undermines scale economics, partner confidence and the firm's ability to fund R&D internally. Without a clear, sustained revenue recovery, the business faces structural challenges to sustaining operations and executing long-term growth plans.
Persistent Negative Cash FlowOngoing negative operating and free cash flows indicate continued cash burn that requires external funding. Over a multi-month horizon, this elevates refinancing risk, potential dilution, and constrains strategic investment, threatening the firm's ability to execute product commercialization.
Sustained Losses And Negative ROENegative ROE and continued losses show the company is not converting capital into shareholder returns. This persistent unprofitability limits reinvestment capacity, reduces investor support for future raises, and represents a structural profitability headwind until margins recover.
Aptamer Group Plc News
APTA FAQ
What was Aptamer Group Plc’s price range in the past 12 months?
Aptamer Group Plc lowest share price was 0.32 p and its highest was 1.57 p in the past 12 months.
What is Aptamer Group Plc’s market cap?
Aptamer Group Plc’s market cap is £16.41M.
When is Aptamer Group Plc’s upcoming earnings report date?
Aptamer Group Plc’s upcoming earnings report date is Oct 20, 2026 which is in 97 days.
How were Aptamer Group Plc’s earnings last quarter?
Aptamer Group Plc released its earnings results on Mar 25, 2026. The company reported 0 p earnings per share for the quarter, the consensus estimate of N/A by 0 p.
Is Aptamer Group Plc overvalued?
According to Wall Street analysts Aptamer Group Plc’s price is currently Overvalued.
Does Aptamer Group Plc pay dividends?
Aptamer Group Plc does not currently pay dividends.
What is Aptamer Group Plc’s EPS estimate?
Aptamer Group Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aptamer Group Plc have?
Aptamer Group Plc has 3,455,144,000 shares outstanding.
What happened to Aptamer Group Plc’s price movement after its last earnings report?
Aptamer Group Plc reported an EPS of 0 p in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -3.846%.
Which hedge fund is a major shareholder of Aptamer Group Plc?
Currently, no hedge funds are holding shares in GB:APTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aptamer Group Plc
Aptamer Group plc, an international company headquartered in York, United Kingdom, specializes in providing advanced binders for applications spanning research, diagnostics, and therapeutics. Their innovative binder technology is engineered to resolve challenges often associated with traditional molecular tools, such as antibodies, offering crucial solutions to bioprocessing, diagnostic, and pharmaceutical scientists. Established in 2014, the company primarily serves pharmaceutical corporations, diagnostic development firms, and various research institutes.
Technical Analysis
Avacta Group plc
―
Bioventix
―
Oxford BioDynamics
―
Fusion Antibodies Plc
―
Arecor Therapeutics PLC
―